The Latest Headlines at American Banking and Market News
Organigram (TSE:OGI) PT Lowered to C$4.35
Organigram (TSE:OGI – Get Free Report) had its price target decreased by equities research analysts at Jefferies Financial Group from C$4.40 to C$4.35 in a research note issued on Friday, BayStreet.CA reports. Jefferies Financial... More of this article »
Research Analysts Set Expectations for HealthEquity, Inc.’s FY2026 Earnings (NASDAQ:HQY)
HealthEquity, Inc. (NASDAQ:HQY – Free Report) – Investment analysts at Zacks Research lifted their FY2026 EPS estimates for HealthEquity in a research note issued to investors on Thursday, May 16th. Zacks Research analyst... More of this article »
Q4 2025 EPS Estimates for Bitdeer Technologies Group (NASDAQ:BTDR) Reduced by Analyst
Bitdeer Technologies Group (NASDAQ:BTDR – Free Report) – Analysts at Roth Capital decreased their Q4 2025 earnings per share estimates for Bitdeer Technologies Group in a research report issued on Tuesday, May 14th.... More of this article »
Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note published on Wednesday morning, Benzinga reports. They currently have a $5.00 target price on the biopharmaceutical... More of this article »
Genfit’s (GNFT) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Genfit (NASDAQ:GNFT – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $11.00 price objective on the stock. Genfit Price Performance Shares... More of this article »
Scotiabank Increases Sabra Health Care REIT (NASDAQ:SBRA) Price Target to $15.00
Sabra Health Care REIT (NASDAQ:SBRA – Free Report) had its price target raised by Scotiabank from $14.00 to $15.00 in a research report sent to investors on Wednesday, Benzinga reports. Scotiabank currently has a sector perform... More of this article »
HC Wainwright Reiterates Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)
HC Wainwright reiterated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $80.00 target price... More of this article »
HC Wainwright Reiterates “Buy” Rating for Daré Bioscience (NASDAQ:DARE)
HC Wainwright restated their buy rating on shares of Daré Bioscience (NASDAQ:DARE – Free Report) in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a $6.00 target price on the... More of this article »
Alphabet (NASDAQ:GOOGL) Earns “Overweight” Rating from Morgan Stanley
Morgan Stanley reaffirmed their overweight rating on shares of Alphabet (NASDAQ:GOOGL – Free Report) in a report published on Wednesday, Benzinga reports. The firm currently has a $195.00 price target on the information services... More of this article »
Palo Alto Networks (NASDAQ:PANW) Rating Reiterated by Morgan Stanley
Morgan Stanley reiterated their overweight rating on shares of Palo Alto Networks (NASDAQ:PANW – Free Report) in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a $360.00 price target... More of this article »
HC Wainwright Reiterates “Buy” Rating for Talphera (NASDAQ:TLPH)
HC Wainwright reissued their buy rating on shares of Talphera (NASDAQ:TLPH – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a $6.00 price objective on the stock.... More of this article »
DURECT (NASDAQ:DRRX) Given Neutral Rating at HC Wainwright
HC Wainwright reissued their neutral rating on shares of DURECT (NASDAQ:DRRX – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright also issued estimates for DURECT’s... More of this article »
Oppenheimer Cuts Gladstone Land (NASDAQ:LAND) Price Target to $16.00
Gladstone Land (NASDAQ:LAND – Free Report) had its price objective lowered by Oppenheimer from $20.00 to $16.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform... More of this article »